Double-Punch therapy trial aims to tame aggressive blood cancer
NCT ID NCT07342244
Summary
This study is testing a new two-step treatment for adults with acute myeloid leukemia (AML) that has returned or not responded to standard chemotherapy. First, patients receive an immune cell therapy (CLL1 CAR-T) designed to target their cancer cells. This is followed by a stem cell transplant from a donor to help rebuild their immune system. The main goal is to see if this combination is safe and can help patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 448000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.